MA-VERACODE
22.11.2022 13:51:37 CET | Business Wire | Press release
Veracode, a leading global provider of modern application security testing solutions, today revealed that almost three-quarters of applications in the retail & hospitality sector contain security flaws, but only 25 percent of these are fixed. Furthermore, 17 percent of these flaws are categorized as ‘high severity’, meaning they pose a serious risk to the business if exploited. With 76 percent of Americans planning to shop the Black Friday sales on 25 November*—and 56 percent planning to purchase entirely online**— retailers should take extra care to reinforce the security of their ecommerce systems, digital payment platforms, and supply chains.
The data was published in Veracode’s annual State of Software Security (SoSS) report v12, which analyzed 20 million scans across half a million applications in the retail, manufacturing, healthcare, financial services, technology, and government sectors.
Chris Eng, Chief Research Officer at Veracode, said, “Maintaining customer loyalty and trust is priority number one for retailers, and this will be heightened during the Black Friday period. With the average cost of a data breach in the retail sector calculated at $3.28 million***, implementing robust tools and practices to secure the applications customers use to browse and make purchases is imperative.”
Despite the relatively low number of flaws that are fixed, the retail industry takes second place for overall remediation rate, highlighting the need for software security improvements from organizations across all sectors. Eng said, “Compared with other sectors, retailers are better at fixing flaws when they’re discovered. While this is encouraging, it’s clear more needs to be done across the board to integrate flaw identification and remediation into the software development pipeline so that vulnerabilities can be addressed more efficiently.”
Server configuration, insecure dependencies, and authentication issues are the most common types of application flaws across most industries. The retail & hospitality sector follows a similar pattern; however, the sector has higher percentages in nearly every flaw category—perhaps due to the greater functional complexity of customer-facing and back-office applications.
Flaw Fix Times Fluctuate in Retail
Veracode analyzed three different scan types to generate industry comparisons for fix times: dynamic analysis security testing (DAST), static analysis security testing (SAST), and software composition analysis (SCA). Retailers were found to be the quickest to address flaws discovered by DAST, at 70 days to reach the halfway point, which is a staggering 46 days faster than financial services in second place. When it came to SAST and SCA, however, the retail sector fell to the middle of the pack, taking 346 days and 470 days respectively to reach the halfway fix point.
Across all industries, flaws in third-party libraries discovered through SCA persist for longer than those found through SAST and DAST, with 30 percent of vulnerable libraries still unresolved after two years. For the retail sector, that statistic rises to 35 percent and lags the cross-industry average by more than six months. Nevertheless, retailers should be assured that the gap is never too wide to close. Indeed, Veracode’s 2021 State of Software Security report found 92 percent of open-source flaws can be easily fixed with a simple update, which is good news for retailers looking to secure their software supply chains.
In the run-up to Black Friday, and nearly one year since the infamous Log4j vulnerability was first reported, retailers will be on high alert to maintain the speed, efficiency, and security of their applications. Businesses should take extra care to uncover vulnerabilities in third-party software using a combination of SCA and development tools. Using this approach with Veracode, Darius Radford, Application Security Architect at specialty retailer Floor & Decor, was able to get a comprehensive view of risk posed by vulnerable libraries in the company’s software: “We were able to quickly figure out all the places running Log4j and remediate the situation.” Trey Tunnel, Floor and Decor’s Chief Information Security Officer, added, “Our customers are our top priority. With Veracode, we have the confidence that our software is secure and—more importantly—our customers have the confidence that our software is secure.”
The Veracode State of Software Security v12 retail & hospitality snapshot is available to download here and the full report is available here.
* Future Publishing, “Exploring the impact of rising inflation”, June 2022, https://go.future-advertising.com/Rising-Inflation-Research-Insights.html
** Dot Digital, “Black Friday Stats: Everything You Need to Know (updated 2022), Jenna Paton, 20 September 2022, https://dotdigital.com/blog/black-friday-cyber-monday-stats/
*** IBM Security and The Ponemon Institute, “Cost of a Data Breach Report 2022”, July 2022, https://www.ibm.com/downloads/cas/3R8N1DZJ
About the State of Software Security Report
The Veracode State of Software Security (SoSS) v12 analyzed the full historical data from Veracode services and customers. This accounts for a total of more than half a million applications (592,720) that used all scan types, more than a million dynamic analysis scans (1,034,855), more than five million static analysis scans (5,137,882) and more than 18 million software composition analysis scans (18,473,203). All those scans produced 42 million raw static findings, 3.5 million raw dynamic findings, and six million raw SCA findings.
The data represents large and small companies, commercial software suppliers, software outsourcers, and open-source projects. In most analyses, an application was counted only once, even if it was submitted multiple times as vulnerabilities were remediated, and new versions uploaded.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005446/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
